Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys

Vaccine

Volumn 32, Issue 35, 2014, Pages 4436-4442

  Wang, Jingjing ^a   Qi, Sudong ^a   Zhang, Xiaolong ^a   Zhang, Ying ^a   Liu, Longding ^a   Che, Yanchun ^a   He, Zhanlong ^a   Zhao, Yuan ^a   Lu, Shuaiyao ^a   Yu, Wenhai ^a   Li, Qihan ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Coxsackievirus A 16 (CA16); Enterovirus 71 (EV71); Immune response; Inactivated vaccine; Rhesus monkey

Indexed keywords

CYTOKINE; INACTIVATED VACCINE; VIRUS VACCINE;

ANIMAL; BLOOD; BODY TEMPERATURE; COXSACKIE VIRUS INFECTION; DISEASE MODEL; ENTEROVIRUS; IMMUNOLOGY; RHESUS MONKEY; VIREMIA; VIRUS SHEDDING;

ANIMALS; BODY TEMPERATURE; COXSACKIEVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; MACACA MULATTA; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA; VIRUS SHEDDING;

EID: 84904389144     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.062     Document Type: Article

References (35)

1. Chan K.P., Goh K.T., Chong C.Y., Teo E.S., Lau G., Ling A.E. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003, 9:78-85.
2. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26:91-107.
3. Chan L.G., Parashar U.D., Lye M.S., Ong F.G., Zaki S.R., Alexander J.P., et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the outbreak study group. Clin Infect Dis 2000, 31:678-683.
4. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., et al. An epidemic of enterovirus 71 infection in Taiwan Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999, 341:929-935.
5. MMWR Deaths among children during an outbreak of hand, foot, and mouth disease-Taiwan, Republic of China, April-July 1998. MMWR Morb Mortal Wkly Rep 1998, 47:629-632.
6. Lum L.C., Wong K.T., Lam S.K., Chua K.B., Goh A.Y., Lim W.L., et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998, 133:795-798.
7. Shimizu H., Utama A., Yoshii K., Yoshida H., Yoneyama T., Sinniah M., et al. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis 1999, 52:12-15.
8. Li J.X., Mao Q.Y., Liang Z.L., Ji H., Zhu F.C. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 2014, 13:609-618.
9. Chang J.Y., Chang C.P., Tsai H.H., Lee C.D., Lian W.C., Ih Jen S., et al. Selection and characterization of vaccine strain for enterovirus 71 vaccine development. Vaccine 2012, 30:703-711.
10. Caine E.A., Partidos C.D., Santangelo J.D., Osorio J.E. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One 2013, 8:e59501.
11. Chen P., Tao Z.X., Wang H.Y., Song Y.Y., Wang X.J., Xu A.Q. Progress in research of new human enterovirus types. Bing Du Xue Bao 2013, 29:211-217.
12. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits a balanced protective immunity against both viruses. Vaccine 2014.
13. Chang H.W., Lin Y.W., Ho H.M., Lin M.H., Liu C.C., Shao H.Y., et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One 2013, 8:e69858.
14. Wang C., You A., Tian X., Zhao M., Chen Y., Lin T., et al. Analysis and solution of false-positives when testing CVA16 sera using an antibody assay against the EV71 virus. Virus Res 2013, 176:33-36.
15. He S.J., Han J.F., Ding X.X., Wang Y.D., Qin C.F. Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in Guangdong, 2010. Int J Infect Dis 2013, 17:e1025-e1030.
16. Zhang Y., Cui W., Liu L., Wang J., Zhao H., Liao Y., et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011, 91:1337-1350.
17. Dong C., Liu L., Zhao H., Wang J., Liao Y., Zhang X., et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011, 29:6269-6275.
18. Yang E., Zhao H., Zhang Y., Liu J., Liao Y., Wang L., et al. A comparative study of the characteristics of two Coxsackie A virus type 16 strains (genotype B). Sci China Life Sci 2012, 55:336-342.
19. Dong C., Wang J., Liu L., Zhao H., Shi H., Zhang Y., et al. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccines 2010, 6:1028-1037.
20. Anim L. Guide for the care and use of laboratory animals 2011, National Academies Press, Washington, DC.
21. Ministry of Science and Technology of the People's Republic of China. China The Guidance to experimental animal welfare and ethical treatment. [updated 2006 Sep 30; cited 2014 Mar 1]. Available from: http://www.most.gov.cn/fggw/zfwj/zfwj2006/200609/t20060930_54389.htm.
22. Arita M., Nagata N., Sata T., Miyamura T., Shimizu H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J Gen Virol 2006, 87:3317-3327.
23. Liang Y., Zhou X., Yang E., Pu J., Che Y., Wang J., et al. Analysis of the Th1/Th2 reaction in the immune response induced by EV71 inactivated vaccine in neonatal rhesus monkeys. J Clin Immunol 2012, 32:1048-1058.
24. Guide for the care and use of laboratory animals 2011, Institute for Laboratory Animal Research, National Academies Press, Washington, DC.
25. Chang L.Y., Huang L.T.Y.Y.H., et al. Comparison of enterovirus 71 and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999, 18:1092-1096.
26. Liu L., Zhao H., Zhang Y., Wang J., Che Y., Dong C., et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 2011, 412:91-100.
27. Liu L., Zhang Y., Wang J., Zhao H., Jiang L., Che Y., et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013, 8:e54451.
28. Gong X., Zhou J., Zhu W., Liu N., Li J., Li L., et al. Excessive proinflammatory cytokine and chemokine responses of human monocyte-derived macrophages to enterovirus 71 infection. BMC Infect Dis 2012, 12:224.
29. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
30. Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013, 381:1037-1045.
31. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.
32. Yang E., Cheng C., Zhang Y., Wang J., Che Y., Pu J., et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccines Immunotherapeutics 2014, 2014.
33. Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012, 86:11967-11976.
34. Li W., Yi L., Su J., Lu J., Ke C., Zeng H., et al. Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period. PLoS One 2013, 8:e80515.
35. Xu G.Z., Ni H.X., Yi B., He T.F., Dong H.J., Fang T., et al. Epidemiological and etiological characteristics of hand-foot-mouth disease in Ningbo, Zhejiang province, 2008-2011. Zhonghua Liu Xing Bing Xue Za Zhi 2013, 34:361-365.